| Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. CT Investigators. N Engl J Med 384 (14), 1289-1300, 2021 | 1216* | 2021 |
| Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior … CN Sternberg, DP Petrylak, O Sartor, JA Witjes, T Demkow, JM Ferrero, ... Journal of clinical oncology 27 (32), 5431, 2009 | 383 | 2009 |
| Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer HM Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF ... N Engl J Med 382 (23), 2197-2206, 2020 | 363* | 2020 |
| Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label … K Fizazi, S Foulon, J Carles, G Roubaud, R McDermott, A Fléchon, ... The Lancet 399 (10336), 1695-1707, 2022 | 354 | 2022 |
| Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer TB Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza ... N Engl J Med 382 (23), 2187-2196, 2020 | 339* | 2020 |
| Chemotherapy with an every‐2‐week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin‐based therapy CN Sternberg, F Calabrò, G Pizzocaro, L Marini, S Schnetzer, A Sella Cancer: Interdisciplinary International Journal of the American Cancer …, 2001 | 246 | 2001 |
| Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer EY Yu, G Wilding, E Posadas, M Gross, S Culine, C Massard, MJ Morris, ... Clinical Cancer Research 15 (23), 7421-7428, 2009 | 244 | 2009 |
| Can patient selection for bladder preservation be based on response to chemotherapy? CN Sternberg, V Pansadoro, F Calabrò, S Schnetzer, D Giannarelli, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 227 | 2003 |
| Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer CN Sternberg, H Dumez, H Van Poppel, I Skoneczna, A Sella, ... Annals of Oncology 20 (7), 1264-1269, 2009 | 133 | 2009 |
| Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer F Calabrò, CN Sternberg european urology 55 (2), 348-358, 2009 | 127 | 2009 |
| Current therapies and advances in the treatment of pancreatic cancer A Mancuso, F Calabrò, CN Sternberg Critical reviews in oncology/hematology 58 (3), 231-241, 2006 | 122 | 2006 |
| Current therapies and advances in the treatment of pancreatic cancer A Mancuso, F Calabrò, CN Sternberg Critical reviews in oncology/hematology 58 (3), 231-241, 2006 | 122 | 2006 |
| Current indications for chemotherapy in prostate cancer patients F Calabrò, CN Sternberg European urology 51 (1), 17-26, 2007 | 109 | 2007 |
| Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma F Calabrò, V Lorusso, G Rosati, L Manzione, L Frassineti, T Sava, ... Cancer 115 (12), 2652-2659, 2009 | 95 | 2009 |
| LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus … K Fizazi, JC Galceran, S Foulon, G Roubaud, R McDermott, A Fléchon, ... Annals of Oncology 32, S1299, 2021 | 76 | 2021 |
| Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder CN Sternberg, V Pansadoro, F Calabro, L Marini, A Van Rijn, P De Carli, ... Annals of oncology 10 (11), 1301-1305, 1999 | 75 | 1999 |
| Does neoadjuvant cisplatin‐based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta‐analysis of individual patient data from randomized … Advanced Bladder Cancer Overview Collaboration:(Collaborators: D. Ghersi LA ... British Journal of Urology 75 (2), 206-213, 1995 | 67 | 1995 |
| Development of the Italian version of the revised Scoliosis Research Society-22 Patient Questionnaire, SRS-22r-I: cross-cultural adaptation, factor analysis, reliability, and … M Monticone, P Baiardi, D Calabrò, F Calabrò, C Foti Spine 35 (24), E1412-E1417, 2010 | 55 | 2010 |
| TK inhibitor pazopanib primes DCs by downregulation of the β-catenin pathway IG Zizzari, C Napoletano, A Botticelli, S Caponnetto, F Calabrò, A Gelibter, ... Cancer immunology research 6 (6), 711-722, 2018 | 52 | 2018 |
| A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive … K Fizazi, X Maldonado, S Foulon, G Roubaud, RS McDermott, A Flechon, ... Journal of Clinical Oncology 39 (15_suppl), 5000-5000, 2021 | 51 | 2021 |
